Nervous Disorder TRIZ Cases

Selective 5-HT2A and 5-HT2C inverse agonist compounds improve hallucination and delusion treatment while reducing cardiovascular side effects.

Salt and cocrystal forms of Compound 1 improve stability, purity, and bioavailability while enabling more reliable IDO drug manufacturing.

A targeted R1 substituent enables DRG-MAOB-1 to selectively inhibit MAO-B over MAO-A, supporting neurodegenerative treatment.

A mixed butyrate-MCFA triglyceride improves taste and odor while supporting butyrate delivery and ketone production with less GI intolerance.

Modified-release polymer matrices sustain T-type calcium channel modulation, extending therapeutic coverage while reducing peak concentration side effects.

A heterocyclic glucosylceramide synthase inhibitor reduces glycosphingolipid accumulation for lysosomal storage and neurodegenerative disease treatment.

Site-specific AAV capsid mutations improve CNS biodistribution and transduction efficiency, boosting brain-region cell expression versus wild type.

Antibodies against the non-phosphorylated tau 396-410 epitope help block extracellular toxic tau spread while sparing physiological tau function.

Clinical data identify older Parkinson's patients as better responders to istradefylline, reducing OFF time with fewer motor complications.

Selective α5-containing GABAA receptor modulation with benzodiazepine derivatives aims to improve cognition across CNS disorders.

Structural variation in GBA2 inhibitors improves enzyme selectivity and brain exposure, supporting glucosylceramide control in CNS and liver disease.

Activin A, bFGF, and amino acid signaling enrich Wnt-activated adipose stem cells, improving purity and safer neurodegenerative treatment.

A pH-activated Aβ dye lights up only in acidic phagosomes, separating internalized amyloid beta from surface-bound signal in microglia.

Blocking Rhes farnesylation with farnesyltransferase inhibitors restores autophagy, clears tau, and reduces neurofibrillary tangles.

Engineered CAR T cells target HER2, IL13Rα2, and EphA2 together to limit antigen escape and improve glioblastoma tumor control.

Using Cordyceps militaris extract, this case shows how pre-inhibiting hormone catabolism helps maintain testosterone and dihydrotestosterone levels.

Human neural stem cells extend treatment beyond hypothermia's narrow window to protect neonatal brain tissue and support recovery.

Selective EP4 antagonists modulate PGE2 signaling to preserve therapeutic effects while reducing the side effects linked to broad COX inhibition.

RAP inhibits LRP1 and pathological RhoA activation to drive OPC differentiation, boost remyelination, and slow MS progression.

Short peptides inhibit NF-κB more directly than TNF-α antagonists, enabling targeted gene modulation across inflammatory and cancer-related disorders.

Fenchol activates FFAR2 signaling to boost proteasome and lysosomal Aβ clearance, reducing neurotoxicity and supporting cognition in Alzheimer's disease.

Digestive enzyme therapy targets GI dysfunction linked to neurological and mental health symptoms, with fecal chymotrypsin guiding diagnosis.

Core-shell 3D printed implants with linear channels and neural stem cells guide axon regrowth while reducing foreign body response.

Liposome encapsulation stabilizes ionizable carotenoids and boosts bioavailability for treating sepsis, hypoxia, and ischemia.

Prodrug modification of A2B adenosine receptor antagonists improves aqueous formulation, plasma level reproducibility, and bioavailability.

A small-molecule PAR2 inhibitor, 1-PPA suppresses receptor RNA synthesis and binding activity to reduce inflammation and platelet aggregation.

Specific promoter, polyadenylation, and serotype choices raise AAV yield and HGF expression after intrathecal delivery.

A 3-9 mg daily nizubaglustat regimen improves function and lowers seizure burden while limiting severe side effects in lysosomal storage disorders.

Bile salts, sunflower oil, and carrier powders improve oral CBD absorption for epilepsy while supporting steady plasma levels and liver enzyme stability.

These derivatives treat fragile X and Rett syndrome deficits while avoiding serotonin, norepinephrine, and dopamine re-uptake inhibition.

An scFv linked to a CMA signal targets early misfolded TDP-43 for autophagic degradation, helping suppress neuronal cell death.

Selective benzimidazole STING antagonists inhibit interferon and ISG signaling to address autoimmune, inflammatory, and cardiovascular disorders.

Polymer-conjugated MMF injections control release and improve pharmacokinetic consistency while reducing GI side effects in RRMS and psoriasis.

Selective N-benzyl-2-phenoxybenzamides improve EP2 and EP4 receptor targeting for cancer, pain, inflammation, and kidney disease treatment.

Low-dose disulfiram and related compounds provide anxiolytic and antidepressant effects while reducing dependence and adverse effects.

Precise sodium and potassium R-beta-hydroxybutyrate ratios improve sustained ketosis, weight management, and blood glucose control.

Combining glutamate, dopamine, receptor, and BDNF-supporting agents improves memory and focus through coordinated multi-pathway action.

Small molecules modulate pre-mRNA splicing while bypassing oligonucleotide steric barriers and poor oral bioavailability.

Surface plasmon resonance apertures enable blood exosome marker detection for earlier, less invasive neurodegenerative diagnosis.

Uses syringaresinol to relieve chemotherapy- or nerve injury-related neuropathic pain while limiting side effects and preserving anticancer activity.

Phosphorothioate backbone conjugates carry non-cell-penetrating proteins into cells to disrupt STAT3 shuttling and trigger cancer cell apoptosis.

FAF1 inhibition with aminopyrazoles lowers alpha-synuclein aggregation and promotes autophagy for synucleinopathy treatment.

Novel substituted benzimidazole PPARα/δ agonists tune molecular substituents to improve pharmacokinetics without sacrificing metabolic activity.

User behavior data is used to detect default inhalation patterns and trigger notifications that keep aerosol ingredient delivery more consistent.

Specific levodopa, carbidopa, and entacapone ratios stabilize plasma levodopa levels to reduce wearing off and motor fluctuations.

Sodium octanoate promotes fatty acid oxidation when glucose use fails after cardiac arrest, improving CPR efficacy and limiting organ dysfunction.

Adding ondansetron to pramipexole reduces emesis and GI side effects, enabling higher antidepressant doses with better tolerability.

Small-molecule amide derivatives inhibit excessive NLRP3 activation to help treat inflammatory and degenerative diseases while preserving immune response.

Selective GABAA γ1 PAM benzodiazepines restore inhibitory signaling in ASD-related brain circuits while reducing sedation from non-selective drugs.

Type I PRMT inhibitors block arginine methylation in dipeptide repeat proteins to reduce neuronal toxicity linked to ALS and FTD.

Modified antibody CDRs block Galectin-3 and LSECtin binding to reverse regulatory T cell suppression and increase IL-2 production.

Crystalline memantine derivatives resolve formulation challenges by enhancing water solubility while reducing adverse effects.

A transdermal patch uses a saturated capsaicin solution within a silicone matrix to deliver active ingredients through the skin.

siRNA sequences inhibit PTEN mRNA to restore neuron regenerative capacity in complete spinal cord lesions.

Humanized anti-TWEAK antibodies use 95% identical framework sequences to minimize immunogenic reactions while maintaining therapeutic efficacy.

A bifunctional protein combines TGFβ neutralization with PD-L1 blockade to activate immune responses.

Targeted LXRβ agonists enhance ABCA1 expression without inducing lipogenesis, resolving metabolic contradictions in diabetes treatment.

Enzymatic glycosylation converts lipophilic cannabinoids into soluble forms, resolving cellular toxicity and enabling homogeneous beverage formulation.

Combining meclofenamic acid with donepezil prolongs cognitive improvement beyond monotherapy limits.

Salmon thrombin gel applied to neural injury sites mitigates microglia activation and inflammatory responses, alleviating central nervous system-mediated pain.

Leukotriene inhibitors treat tumors by targeting specific receptors, reducing side effects compared to conventional agents.

Small molecule compounds inhibit the dual-leucine zipper kinase pathway to promote retinal ganglion cell survival.

Ofatumumab maintains serum IgG levels to reduce serious infection risks in Asian multiple sclerosis patients.

Administering antibodies specific to caveolin-1 modulates microglia polarization, reducing neuronal death and improving functional recovery after stroke.

A treatment regimen restores intestinal barrier function using tyrosine hydroxylase inhibition to modulate adrenaline secretion.

A nutritional composition lowers brain phenylalanine levels using large neutral amino acids to compete at the blood-brain barrier.

Highly concentrated medicant solutions administered directly to the brain via catheters maintain therapeutic levels of short half-life drugs.

Sulfono-gamma-AA peptides resist proteolytic degradation to reduce amyloid beta aggregation and improve working memory in neurodegenerative disease models.

Sacubitril and valsartan combination therapy reduces central blood pressure and pulse wave velocity through dual receptor blocking and enzyme inhibition.

Engineered humanized antibodies target toxic amyloid-beta oligomers to treat Alzheimer's disease.

Trypsin mutants enable site-specific PEG transfer via intermediary peptides, reducing immunogenicity and proteolytic cleavage.

Optimized pH and purification remove chlorate impurities, reducing systemic toxicity for safe intravenous administration.

Pyridine-3,4-diamine blocks potassium channels to treat post-COVID fatigue where immunomodulatory therapies lack clear scientific results.

Novel kinase inhibitory compounds selectively inhibit RIP1 activity, resolving persistent inflammation and tissue damage in inflammatory diseases.

Segmented prominin-1 fragments provide controlled angiogenesis without excessive vessel formation.

A recombinant vector encoding amyloid beta and interleukin-4 drives a Th2 response that clears plaques while avoiding encephalitis.

Combines cilnidipine with p-glycoprotein inhibitors to enhance analgesic bioavailability.

Adsorbent carrier extracts amyloid beta protein from blood via physical interaction, reducing brain concentration without immune side effects.

Interferon gamma upregulates frataxin expression to rescue aconitase defects and improve motor coordination in Friedreich's ataxia.

A combination therapy comprising glibenclamide, exenatide, and potassium canrenoate delivers neuroprotective effects.

Hc-TeTx overcomes delayed onset and side effects by increasing BDNF.

Antisense oligonucleotides hybridize with Grik2 mRNA to reduce aberrant hippocampal activity while minimizing off-target effects.

Glutamate modulators normalize neurotransmitter levels to resolve treatment-resistant obsessive-compulsive disorder symptoms.

Antibodies bind misfolded transthyretin to inhibit aggregation, preventing tissue damage from amyloid deposits.

Anti-ALK2 antibodies bind and cross-link ALK2 receptors to inhibit BMP signal transduction.

Humanized antibody E3 binds nerve growth factor with high affinity, resolving the human anti-murine response while maintaining pain relief efficacy.

Segmenting tau phosphorylation measurements across multiple sites improves diagnostic accuracy while reducing system complexity and measurement time.

A pharmaceutical composition using fermented steam-dried ginseng berries to enhance cognitive function and spatial perception.

An anti-prion monoclonal antibody binds prion protein to inhibit toxic oligomer interactions.

Carbon monoxide treated mesenchymal stem cells reduce augmented Th17 and Th9 cytokines to address underlying immune dysregulation in bipolar disorder.